<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02402049</url>
  </required_header>
  <id_info>
    <org_study_id>PMS-14</org_study_id>
    <nct_id>NCT02402049</nct_id>
  </id_info>
  <brief_title>Homeopathic Treatment of Premenstrual Syndrome</brief_title>
  <official_title>Is Homeopathic Treatment a Placebo Treatment? - Homeopathic Treatment of Premenstrual Syndrome- A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaare Zedek Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaare Zedek Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will focus on premenstrual syndrome (PMS) symptom alleviation for women
      diagnosed as suffering from the syndrome with the DRSP questionnaire.

      The women will be treated with Homeopatic remedies. The improvement of PMS symptoms will be
      evaluated using the Daily Record of Severity of Problems questionnaire (DRSP). The
      questionnaire will be completed daily by women for 2 months prior to receiving the treatment
      and for 3 months following treatment with a single dose of the homeopathy treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Premenstrual syndrome (PMS) is a set of physical, emotional and behavioral symptoms that
      occur during the week preceding menstruation and which alleviate when the menstrual flow
      begins. PMS affects millions of women during their reproductive years. Mild symptoms, which
      usually do not interfere with daily activities, are experienced occasionally by almost all
      ovulatory women. Between 8-30% of ovulatory women suffer from moderate to severe PMS
      symptoms, which may even require treatment. The more severe form of PMS, premenstrual
      dysphoric disorder is considered to affect up to 8% of ovulatory women. This severe form is
      associated with severe disruptions in work function, family, or social relationships. To
      date, therapeutic interventions are insufficient and ranges from stress reduction and
      lifestyle changing to hormonal therapies and the use of psychotropic medications. While
      traditional medications do not necessarily offer satisfactory alleviation of PMS symptoms
      homeopathy can offer a significant alleviation of PMS symptoms for an extended period of
      time.

      The proposed study will focus on PMS symptom alleviation for women diagnosed as suffering
      from the syndrome with the DRSP questionnaire.

      Five Homeopathic remedies (Natrum muriaticum, Lachesis, Sepia, Nux vomica and Pulsatilla )
      will be used, in five different therapy groups. The women will be allocated to the groups
      according to their matching to the remedy according to Homeopathic principles. In each group
      the women will either be treated with the appropriate remedy or with a placebo remedy. Women
      who do not match any of these five groups will be allocated to a sixth group receiving either
      Folliculinum that is given as general indication for PMS in homeopathy or placebo.

      The improvement of PMS symptoms will be evaluated using the Daily Record of Severity of
      Problems questionnaire at (DRSP). The questionnaire will be completed daily by women for 2
      months prior to receiving the treatment and for 3 months following treatment with a single
      dose of the homeopathy treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in the average DRSP questionnaire scores during the 12 days prior to menstruation during three months following single dose homeopathy treatment as compared to the average DRSP questionnaire scores during the 12 days prior to menstruation during</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decreased work absence during the 3 months after therapy begin as compared to the 2 months prior to homeopathy treatment.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the amount of painkillers taken by the patient during the 3 months after homeopathy treatment as compared to the amount of medications taken by the patient during 2 months prior to therapy begin.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-report of the efficiency of the homeopathy treatment.</measure>
    <time_frame>3 months</time_frame>
    <description>The patient will indicate subjectivlly her filling after taking the homeopathic remedy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects occurrence during therapy (e.g headaches, vomiting, nausea etc.)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Premenstrual Syndrome-PMS</condition>
  <arm_group>
    <arm_group_label>1: Natrum muriaticum 30C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Natrum muriaticum 30C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Lachesis 30C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lachesis 30C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: Sepia 30C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sepia 30C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4: Nux vomica 30C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nux vomica 30C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5: Pulsatilla 30C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulsatilla 30C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 Folliculinum 30C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Folliculinum 30C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1: Placebo Natrum muriaticum</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Natrum muriaticum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Placebo Lachesis</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Lachesis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: Placebo Sepia</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Sepia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4: Placebo Nux vomica</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Nux vomica</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5: Placebo pulsatilla</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pulsatilla</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6: Placebo Folliculinum</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Folliculinum</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natrum muriaticum 30C</intervention_name>
    <description>3 globules of Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.</description>
    <arm_group_label>1: Natrum muriaticum 30C</arm_group_label>
    <other_name>Active Natrum muriaticum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lachesis 30C</intervention_name>
    <description>3 globules of Lachesis applied once daily at days 7,8, and 9 after the start of the period.</description>
    <arm_group_label>2: Lachesis 30C</arm_group_label>
    <other_name>Active Lachesis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sepia 30C</intervention_name>
    <description>3 globules of Sepia applied once daily at days 7,8, and 9 after the start of the period.</description>
    <arm_group_label>3: Sepia 30C</arm_group_label>
    <other_name>Active Sepia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nux vomica 30C</intervention_name>
    <description>3 globules of Nux vomica applied once daily at days 7,8, and 9 after the start of the period.</description>
    <arm_group_label>4: Nux vomica 30C</arm_group_label>
    <other_name>Active Nux vomica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pulsatilla 30C</intervention_name>
    <description>3 globules of Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.</description>
    <arm_group_label>5: Pulsatilla 30C</arm_group_label>
    <other_name>Active Pulsatilla</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folliculinum 30C</intervention_name>
    <description>3 globules of Folliculinum applied once daily at days 7,8, and 9 after the start of the period.</description>
    <arm_group_label>6 Folliculinum 30C</arm_group_label>
    <other_name>Active Folliculinum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Natrum muriaticum</intervention_name>
    <description>3 globules of placebo Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.</description>
    <arm_group_label>1: Placebo Natrum muriaticum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Lachesis</intervention_name>
    <description>3 globules of placebo Lachesis applied once daily at days 7,8, and 9 after the start of the period.</description>
    <arm_group_label>2: Placebo Lachesis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Sepia</intervention_name>
    <description>3 globules of placebo Sepia applied once daily at days 7,8, and 9 after the start of the period.</description>
    <arm_group_label>3: Placebo Sepia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Nux vomica</intervention_name>
    <description>3 globules of placebo Nux vomica applied once daily at days 7,8, and 9 after the start of the period.</description>
    <arm_group_label>4: Placebo Nux vomica</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pulsatilla</intervention_name>
    <description>3 globules of placebo Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.</description>
    <arm_group_label>5: Placebo pulsatilla</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Folliculinum</intervention_name>
    <description>3 globules of placebo Folliculinum applied once daily at days 7,8, and 9 after the start of the period.</description>
    <arm_group_label>6: Placebo Folliculinum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 50 years.

          -  Suffers from the PMS, confirmed by the DRSP questionnaire, for at least one year

          -  Read and write in

          -  Signing the informed consent form

        Exclusion Criteria:

          -  Comorbidity.

          -  Use of medications.

          -  Menstruation complains which do not correlate to the menstruation cycle.

          -  Inability to be in a daily contact with the experiment center (e.g., by phone,
             electronically).

          -  Participating in another clinical trial in the last 30 days.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Menachem Oberbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Center for Inegrative Complementary Medicine, Shaare Zedek Medical Center, Jerusalem, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Menachem Oberbaum, MD</last_name>
    <phone>+972-2-6666395</phone>
    <email>oberbaum@szmc.org.il</email>
  </overall_contact>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2015</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2015</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Premenstrual Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

